About Evergreen Theragnostics
Evergreen Theragnostics is a company based in Jersey City (United States) founded in 2019 was acquired by Lantheus in January 2025. Evergreen Theragnostics has raised $75.91 million across 4 funding rounds from investors including Lantheus, Liftt and Petrichor. Evergreen Theragnostics offers products and services including CDMO Products and Radiopharmaceuticals. Evergreen Theragnostics operates in a competitive market with competitors including Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and Dotmatics, among others.
- Headquarter Jersey City, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evergreen Theragnostics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evergreen Theragnostics
Evergreen Theragnostics offers a comprehensive portfolio of products and services, including CDMO Products and Radiopharmaceuticals.
Contract development for therapeutic pipelines in healthcare
Products designed to enhance cancer patient options via theragnostics
People of Evergreen Theragnostics
Unlock access to complete
Leadership Team
1 people
Sales and Marketing
1 people
Microbiology Team
1 people
Legal and Compliance
1 people
Unlock access to complete
Funding Insights of Evergreen Theragnostics
Evergreen Theragnostics has successfully raised a total of $75.91M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $26 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evergreen Theragnostics
Evergreen Theragnostics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Lantheus, Liftt and Petrichor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Petrichor is engaged in supporting healthcare innovation through investments.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Developer of diagnostic imaging agents and targeted therapeutics
|
Locked | Locked | Locked |
Investor details for Evergreen Theragnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evergreen Theragnostics
Investment portfolio details for Evergreen Theragnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evergreen Theragnostics
Detailed financials for Evergreen Theragnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evergreen Theragnostics Comparisons
Peer comparison for Evergreen Theragnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evergreen Theragnostics
Evergreen Theragnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and Dotmatics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services for small molecules are provided.
|
|
| Locked | Locked | Locked |
CDMO services for pharma, biotech, and specialty ingredients are provided.
|
|
| Locked | Locked | Locked |
Pharmaceutical products for treating multiple diseases are provided.
|
|
| Locked | Locked | Locked |
Generic drugs and clinical research services are provided globally.
|
|
| Locked | Locked | Locked |
AI powered scientific data management and workflow automation solutions
|
|
| Locked | Locked | Locked |
Laboratory testing, clinical trial research, and biopharma services are provided.
|
Detailed competitors of Evergreen Theragnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evergreen Theragnostics
Complete news archive for Evergreen Theragnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evergreen Theragnostics
Evergreen Theragnostics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Evergreen Theragnostics is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
James Cook is the current CEO of Evergreen Theragnostics.
Evergreen Theragnostics is a funded company, having raised a total of $75.91M across 4 funding rounds to date.
Evergreen Theragnostics was founded in 2019 and is based in Jersey City, United States. Operations are centered in the radiopharmaceutical sector, where manufacturing of specialized compounds for therapeutic and diagnostic uses is conducted. Regulatory services are offered to ensure compliance with industry standards. The company supports clients in developing and commercializing radiopharmaceutical products, with leadership directed by CEO James Cook. Focus remains on precision medicine applications within biotechnology.
Evergreen Theragnostics offers CDMO Products and Radiopharmaceuticals.